Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -158.27% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTVerrica Pharmaceuticals Inc.'s latest supported as-filed period reports revenue of $5.9M, 53.8% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -158.27% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -53.85% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 46.26% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -223.42% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 102.93% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 20.69% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -27.3% from the comparable as-filed period.
Inventory changed +7.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Net income changed -6547.5% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
VRCA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002046750-26-000004SEC ↗4Aug 18, 2026Period Aug 17, 20260001579649-26-000005SEC ↗4Aug 18, 2026Period Aug 14, 20260002043558-26-000005SEC ↗4Aug 18, 2026Period Aug 18, 20260001556327-26-000003SEC ↗10-QAug 6, 2026Period Jun 30, 20260001660334-26-000025SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-338273SEC ↗4Jun 9, 2026Period Jun 5, 20260001814892-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 18, 2026 | Zawitz DavidChief Operating Officer | Open Market PurchaseDirect | 6,000 | $5 | $29,880 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -967.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed -23531 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed +226.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Revenue changed -53.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001814338-26-000002